Citations

Clear

6729 citation(s) found for "Li, Mark".

Lack of association between rifaximin and drug-resistant infections: a global multicenter inpatient cirrhosis cohort
Bajaj, Jasmohan S, Kamath, Patrick S, Wong, Florence, Xie, Qing, Topazian, Mark, Seto, Wai-Kay, Torre, Aldo, Hayes, PC, Silva, Mario, Bush, Brian J., Choudhury, Ashok, Investigators, On behalf of the EXPLANTORREDO-TAVR Registry, Fisseha, Henok , Fisseha, Henok , Bajaj, Jasmohan S. , Kamath, Patrick S. , Wong, Florence , Xie, Qing , Idılman, Ramazan , Seto, Wai‐Kay , George, Jacob , Alvares-da-Silva, Mario, BUSH, BRIAN J. , Silvey, Scott , Choudhury, Ashok

Mayo Clinic

Clinical and Molecular Hepatology | April 15, 2026 | Volume: 32 | Issue: 3 | Pages: 1321-1332

10.3350/cmh.2026.0228 | PMID 42120075 Get It

Background/Aims: Infections with drug-resistant organisms (DROs) are associated with poor outcomes in cirrhosis. Rifaximin, widely used for hepatic encephalopathy (HE), could promote cross-resistance, but data regarding clinical impact are conflicting. Aim: Determine predictors of DROs in a global cirrhosis inpatient cohort focusing on preadmission rifaximin use.Methods: From the global CLEARED consortium, we focused on cirrhosis inpatients with infections on/during admission. Clinical/demographic/medication, especially rifaximin details were recorded. The primary outcome was DRO development. Multivariable regression for DRO including clinical, medications, and country income was performed.Results: 2,949 infected inpatients (55.3 years, 62.9% male) were included. 12.2% of all and 24.4% of culture-positive infections developed DROs; these patients had higher HE (39 vs. 31%, <i>P</i>=0.003), hepatorenal syndrome (25 vs. 19%, <i>P</i>=0.006), lactulose (55 vs. 47%, <i>P</i>=0.008) and rifaximin use (34 vs. 27%, <i>P</i>=0.006) on crude comparisons but country-income distributions were similar. 29.7% were on pre-admission rifaximin, mostly HE-related; they had more advanced cirrhosis and from low/low-middle-income countries. Daptomycin was used in 1.5%, linked with DROs (5.0 vs. 1.0%, <i>P</i><0.0001) without a difference in rifaximin use (1.4 vs.1.7%, <i>P</i>=0.61). On adjusted analysis, MELD-Na (1.03, 95% CI 1.02–1.04, <i>P</i><0.001) increased, whereas male sex (0.73, 95% CI 0.58–0.92, <i>P</i>=0.008) and hepatitis-B (0.65, 95% CI 0.45–0.92, <i>P</i>=0.020) decreased DRO. Rifaximin was not associated with DROs overall (OR 1.07, 95% CI 0.80–1.43, <i>P</i>=0.65) or within income strata (high: 1.07, 95% CI 0.59–1.92, <i>P</i>=0.82, upper-middle: 1.18, 95% CI 0.74–1.85, <i>P</i>=0.49, low/low-middle: 1.04, 95% CI 0.60–1.81, <i>P</i>=0.90) despite sensitivity analyses.Conclusions: In this large global cohort of hospitalized patients with cirrhosis and infections, 12% developed infections involving DROs. 30% had pre-admission rifaximin use which was not linked with daptomycin use or with DRO development on adjusted analysis overall or across country income groups.
The Efficacy of Bracing in Nonoperative Care of Medial Femoral Condyle Osteochondritis Dissecans: A Study From the Research in Osteochondritis Dissecans of the Knee (ROCK) Study Group
Group, The ROCK, Nissen, Carl W. , Albright, Jay C. , Anderson, Christian N. , Busch, Michael T., Carey, James L. , Carlson, Cathy , Carsen, Sasha , Crepeau, Allison, Edmonds, Eric W. , Ellermann, Jutta , Ellis, Henry B. , Erickson, John B. , Godin, Jonathan , Ganley, Theodore J. , Grimm, Nathan L. , Heyworth, Benton E. , Po, James Hui Hoi, Kocher, Mininder S., Koehler, Ryan, Latz, Kevin, Loveland, Dustin M., Lyon, Roger M., Meenen, Norbert M., Milewski, Matthew D., Myer, Gregory D., Nelson, Bradley J., Nepple, Jeffrey, Nguyen, Jie C. , Paterno, Mark V. , Pennock, Andrew T. , Perkins, Crystal A. , Polousky, John D. , Riley, Pat, Saluan, Paul, Shea, Kevin G., Tompkins, Marc , Wall, Eric J. , Willimon, S. Clifton , Wright, Rick W. , Shea, Kevin G. , Edmonds, Eric W , Ellis, Henry B , Fabricant, Peter D , Ganley, Theodore J , Green, Daniel W , Heyworth, Benton E , Krych, Aaron J , Pace, J Lee , Pennock, Andrew T , Perkins, Crystal A , Tompkins, Marc A , Nissen, Carl , Busch, Michael T., Carlson, Cathy, Chambers, Henry G. , Godin, Jonathan, Hui, James Hoi Po, Kocher, Mininder Singh , Koehler, Ryan J. , Krych, Aaron J. , Lyon, Roger, Meenen, N. M., Milewski, Matthew D. , Myer, Gregory D. , Nelson, Bradley J. , Nepple, Jeffrey J. , Weiss, Jennifer M., Wilson, Philip L. , Kostyun, Regina O.

Mayo Clinic

The American Journal of Sports Medicine | April 15, 2026 | Volume: 54 | Issue: 6 | Pages: 1415-1422

10.1177/03635465261429407 | PMID 41981903 Get It

Background: Stable osteochondritis dissecans (OCD) lesions are primarily treated nonoperatively. Nonoperative treatment includes several recommendations, including the use of an unloader brace. However, little is known about the clinical effectiveness of unloader bracing and its influence on OCD healing, return to sports, and patient-reported outcomes (PROs). The purpose of this investigation was to evaluate the impact of unloader bracing on patients with stable medial femoral condyle (MFC) OCD lesions treated nonoperatively. Purpose: To investigate the influence of valgus unloader bracing on the success of treating stable MFC OCD with nonoperative treatment strategies. Study Design: Cohort study; Level of evidence, 2. Methods: The authors used a prospective cohort of patients receiving nonoperative care for stable MFC knee OCD lesions. The primary variable of interest was the efficacy of bracing. The primary outcomes were transition from nonoperative care to surgical intervention, return-to-play (RTP) clearance, and PROs. Bivariate testing was used to determine if there were differences between groups. Chi-square testing was used to determine if there were differences in rates of transition to surgery by group. The timing of the transition by each group was assessed using a Wilcoxon rank-sum test, given the nonparametric nature of the data. Kaplan-Meier survival analysis was used to calculate time at risk, incidence rate, and survival times for each group. Results: A total of 185 knees (bracing group: 123 [66.5%] knees; no-bracing group: 62 [33.5%] knees) were analyzed. Overall, 142 (76.8%) knees were successfully treated nonoperatively. Transition to surgery occurred in 43 (23.2%) knees. There were no differences in transition to surgery by groups, with no differences seen by group. Of the knees that did not transition to surgical care, 65 (71.4%) in the bracing group and 38 (74.5%) in the no-bracing group received RTP clearance ( P = .693). PRO scores were similar between the 2 groups at the time of RTP clearance. Conclusion: The inclusion of an unloader brace in the nonoperative treatment for stable MFC OCD lesions did not decrease the likelihood of patients undergoing surgical intervention or improve their PRO scores at the time of RTP clearance. Registration: NCT02771496 (ClinicalTrials.gov identifier).
Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial
Wen, Patrick Y. , Berry, Donald A. , Buxton, Meredith , Colman, Howard , Groot, John de , Lim, Michael, Mellinghoff, Ingo K. , Perry, James, Weller, M, Blondin, Nicholas A., Butt, Omar H. , Damek, Denise M., Fuente, Macarena I. de la , Drappatz, Jan, Dunbar, Erin, Giglio, Pierre , Hyddmark, Emma Viktoria, Iwamoto, Fabio, Jaeckle, Kurt A. , Kim, Lyndon, Kling, Heather M., Lee, Eudocia Q., Mantica, Megan , Mikkelsen, Tom, Newton, Herbert B. , Walbert, Tobias , Weathers, Shiao‐Pei , Lassman, Andrew B. , Group, for the GBM AGILE Regorafenib Study, Alexander, Brian, Anker, Lars , Berry, Nicholas , Cloughesy, Tim, Connelly, Jennifer , Detry, Michelle A. , Fitzgerald, Mark, Gordon, Gary, Graves, Todd, Hu, Jethro , Hyddmark, Emma Maria Viktoria, Johnson, Adam, Kalabic, Marija, Lesser, Glenn J., Marion, Joe , Owen, Scott, Perry, James R, Peters, Katherine B., Powell, Ashley, Saunders, Christina T., Tanner, Kirk, Untch, Sarah, Wilcox, Emma, Yung, W. K. Alfred, Lim, Michael , Buxton, Meredith , de Groot, John , Mellinghoff, Ingo K , Weller, Michael , De La Fuente, Macarena , Lee, Eudocia Q , Mantica, Megan , Nabors, Louis Burt , Newton, Herbert B , Olson, Jeffrey J. , Schiff, David , Walbert, Tobias , Weathers, Shiao-Pei , Cloughesy, Timothy F , Lassman, Andrew B , Berry, Donald , Colman, Howard , Blondin, Nicolas, Drappatz, Jan , Iwamoto, Fabio M., Lee, Eudocia Q. , Mikkelsen, Tom , Nabors, Burt , Newton, Herbert B. , Cloughesy, Timothy F. , Anderson, Mark D., Cavenee, Webster K. , Connelly, Jennifer , Ellingson, Benjamin M. , Galanis, Evanthia , Gordon, Gary, Graber, Jerome J. , Khasraw, Mustafa , Lesser, Glenn J. , McGlothlin, Anna , Peters, Katherine B. , Saunders, Christina T. , Sulman, Erik P. , Tanner, Kirk, Yung, W.K. Alfred

Mayo Clinic

Journal of Clinical Oncology | April 14, 2026 | Volume: 44 | Issue: 18 | Pages: 1676-1686

10.1200/jco-25-01137 | PMID 41980234 Get It

PURPOSE GBM AGILE (ClinicalTrials.gov identifier: NCT03970447 ) is a phase II/III Bayesian adaptive platform registration trial testing multiple arms against a common control; the primary end point is overall survival (OS). Regorafenib, a multikinase inhibitor, showed OS benefit in recurrent (RD) glioblastoma in the phase II REGOMA trial and entered GBM AGILE as the first investigational arm. METHODS Patient subtypes included in the regorafenib arm of GBM AGILE were newly diagnosed unmethylated (NDU) and RD glioblastoma. Prospective defined sets of subtypes, or arm signatures, were NDU, RD, and all (NDU + RD). As the first investigational arm in GBM AGILE, regorafenib was equally randomized to the control arm. Treatment in the control arm is temozolomide + radiotherapy (in newly diagnosed) or lomustine (in RD). Efficacy was assessed by OS hazard ratio (HR), arm/control, and demonstrated when the Bayesian probability of benefit (HR <1.00) was ≥98%. Analysis was performed monthly for limited efficacy, which occurs when the Bayesian predictive power is <25% for all signatures, and determines stopping enrollment. Follow-up continued for 12 months after accrual stopped. RESULTS When the predictive power was <25% in all predefined signatures for regorafenib, accrual stopped for limited efficacy. The final analysis did not demonstrate OS improvement in the regorafenib arm in RD nor NDU glioblastoma. Median HRs were 1.05 (NDU), 1.07 (RD), and 1.07 (all) with final probabilities of benefit (HR <1.00) of 0.421 (NDU), 0.312 (RD), and 0.296 (all). Regorafenib was associated with increased toxicity relative to control. CONCLUSION GBM AGILE did not show superiority of regorafenib over control in RD (lomustine) or NDU (temozolomide + radiotherapy) glioblastoma, yet caused increased toxicities. Regorafenib has been removed from National Comprehensive Cancer Network guidelines as a treatment option for RD.
Discovery and Preclinical Validation of a Clinically Optimized Mitochondrial Complex I Modulator for Alzheimer’s Disease
Trushin, Sergey , Nguyen, Thi Kim Oanh , Ostroot, Mark , Galkin, Alexander , Nambara, Toshihiko , Lu, Wenyan , Kanekiyo, Takahisa , Johnson, Graham, Trushina, Eugenia , Ostroot, Mark , Nambara, Toshihiko , Trushina, Eugenia

Mayo Clinic

No container title available | April 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.04.10.717554 | PMID 42039405 Get It

Abstract Alzheimer’s disease (AD) is characterized by diminished capacity to mount adaptive cellular stress responses required to maintain energy homeostasis and proteostasis. An emerging therapeutic strategy is to restore adaptive stress responses by inducing mild energetic stress through inhibition of mitochondrial complex I (mtCI). However, pharmacological inhibition of the respiratory chain has remained challenging, as it can induce bioenergetic failure rather than beneficial signaling. Here, we describe C273, a brain-penetrant small molecule that delivers controlled, weak attenuation of mtCI activity to therapeutically restore endogenous adaptive stress pathways. This work establishes a first-in-class mechanism in which calibrated activation of multifaceted adaptive mechanisms enhances cellular resilience, rather than impairing mitochondrial function. Structure-activity relationship optimization yielded a compound with high potency against Aβ-induced cellular toxicity, strong selectivity for mtCI, and favorable drug-like properties. C273 demonstrated excellent oral bioavailability, metabolic stability in mouse, rat, and human microsomes, minimal CYP liabilities, and a clean ancillary pharmacology profile in the Eurofins CEREP44 panel. In vivo , C273 readily crosses the blood-brain barrier and activates AMP-activated protein kinase (AMPK), initiating a coordinated hormetic response characterized by enhanced antioxidant defenses, suppression of inflammatory signaling, induction of autophagy, and increased mitochondrial biogenesis and turnover. Genetic deletion of AMPKα1/α2 abolished these responses, establishing AMPK as a critical mediator of C273 activity. Pharmacological competition experiments further confirmed the target, as pretreatment with non-toxic concentrations of rotenone blocked C273 interaction with the quinone-binding site of mtCI and eliminated its neuroprotective effects. Repeated oral administration of C273 (20-80 mg/kg/day) to wild-type mice for one month produced no detectable cardiac or hepatic toxicity, indicating a favorable in vivo safety margin. Importantly, C273 activated these mechanisms and reduced Aβ and p-Tau levels in induced pluripotent stem cell-derived cerebral organoids from patients with sporadic AD. Collectively, these results establish controlled mtCI modulation as a therapeutic strategy and position C273 as a promising disease-modifying candidate for AD.
Clinical benefits and current challenges of photon-counting detector CT in vascular imaging
Sadaney, Ahmed O El , Mark, Ian, Froemming, Adam T. , Baffour, Francis , Yu, Lifeng, Leng, Shuai, McCollough, Cynthia H, Leng, Shuai , El Sadaney, Ahmed O , Rajiah, Prabhakar Shantha, Campeau, Norbert G , Froemming, Adam T , Baffour, Francis I , Horst, Kelly K. , Yu, Lifeng , Leng, Shuai , McCollough, Cynthia H , Fletcher, Joel G , Diehn, Felix E. , Rajiah, Prabhakar , Mark, Ian, Campeau, Norbert G. , McCollough, Cynthia H. , Fletcher, Joel G.

Mayo Clinic

Radiology Advances | April 14, 2026 | Volume: 3 | Issue: 3 | Pages: No page available

10.1093/radadv/umag021 | PMID 42254812 Get It

Abstract Photon-counting detector CT (PCD-CT) directly detects individual photons and measures their energies, enabling the acquisition of multi-energy data from a single x-ray source with higher spatial resolution, thereby allowing visualization of smaller arteries and veins and other important imaging features not seen at conventional CT. It also substantially reduces calcium and stent blooming artifacts. Appropriate patient selection and task-based optimization of acquisition, reconstruction, and interpretation are critical to realize these benefits. Vascular imaging examinations for which early evidence shows that PCD-CT demonstrates higher diagnostic performance compared to conventional CT include coronary CT angiography (CTA) for evaluation of partially calcified plaques or stents, peripheral runoff CTA, detection of cerebrospinal fluid-venous fistulas, and head CTA for evaluation of small intracranial vessels and aneurysms. Current limitations include excessive image noise with the sharpest reconstruction kernels and challenges when adapting conventional CT protocols (eg, requiring sharper kernels, thinner slices, higher matrices, tailored scan modes) to achieve time-efficient image reconstruction and hanging protocols. New solutions and directions will include deep-learning-based image noise reduction, improved spectral separation, strategic triage of specific patient populations to PCD-CT systems, and subspecialty clinical practice recommendations for this new technology.
A Retrospective, Comparative Cohort Analysis of the Utilization of Voriconazole-Containing Regimens Versus Itraconazole in the Treatment of Blastomycosis
Schanz, Caitlin , Rivera, Christina G. , Saleh, Omar M. Abu, Clement, Josh , Enzler, Mark J., Firkus, Danielle , Mara, Kristin C. , Vergidis, Paschalis , Stevens, Ryan W. , Schanz, Caitlin C , Mara, Kristin C , Vergidis, Paschalis , Rivera, Christina G , Stevens, Ryan W , Schanz, Caitlin C., Saleh, Omar Abu

Mayo Clinic

Journal of Fungi | April 14, 2026 | Volume: 12 | Issue: 4 | Pages: 279

10.3390/jof12040279 | PMID 42042373 Get It

Itraconazole is the recommended first-line antifungal agent in blastomycosis treatment. However, pharmacokinetic limitations and adverse drug events may necessitate the use of alternative antifungal agents. The primary objective of the study was to retrospectively describe a cohort of patients with blastomycosis who received voriconazole (as partial or complete therapy), for complete or partial treatment, compared to those who received itraconazole alone. Secondary objectives included rationale for voriconazole selection, treatment response, mortality, and adverse drug events. This retrospective multicenter cohort study included adult patients with proven/probable blastomycosis who received itraconazole or voriconazole. Treatment response was evaluated at one year or end of therapy, whichever came first. Mortality outcomes were assessed within 7 days of the last documented azole dose. Propensity score weighting and subgroup analysis were utilized to control confounding variables between cohorts. A total of 119 patients receiving itraconazole and 25 receiving voriconazole as complete or partial treatment were included. Voriconazole was often selected for CNS involvement or after intolerance to alternative azoles. After propensity score weighting, no significant difference in complete or partial treatment response was observed. Rates of all-cause mortality and blastomycosis-related mortality were numerically higher in the voriconazole cohort. Adverse drug event rates were similar between cohorts; however, discontinuation due to adverse events was more common in the voriconazole cohort. Voriconazole was most utilized for the treatment of blastomycosis in cases with CNS involvement or intolerance to other azoles. A statistically significant difference in response rate was not identified between voriconazole-containing or itraconazole-treated patients; however, given limited sample sizes, further data is needed to assess the equivalency of these agents in the treatment of blastomycosis.
Incidence of infective endocarditis following surgical or transcatheter mitral valve repair or replacement: a systematic review and meta-analysis
Vibhishanan, Jonathan , Zorman, Mark , Malik, Basimah T, Coronelli, Marco , Kumar, Akshaya, Hampshire, Jonathan , Heylen, Katherine, Choksey, Anurag , Eastwick-Jones, Kate , Newton, James D. , Prendergast, B, Cahill, T, Zorman, Mark J , Dawkins, Sam , Prendergast, Bernard , Cahill, Thomas J.

Mayo Clinic

European Heart Journal - Valvular and Structural Heart Disease | April 13, 2026 | Volume: 2 | Issue: 2 | Pages: No page available

10.1093/ehjvshd/xwag030 Get It

Abstract Aims Infective endocarditis (IE) is a serious and potentially fatal complication of mitral valve (MV) intervention. There are limited data comparing the incidence of IE after MV repair compared with bioprosthetic MV replacement. The aim of this study was to analyse the incidence and timing of IE after MV repair compared with bioprosthetic valve replacement, in both surgical and transcatheter patient populations. Methods and results A literature search of Medline, Embase, and Cochrane Library (January 2000—September 2025) was conducted. Pooled IE incidence rates were derived using random-effects models. Eighty-two studies (80 939 patients, total follow-up 350 252 patient-years) were included. The overall incidence rate of IE was 0.97 per 100-patient-years (95% confidence interval [CI] 0.71–1.34). IE was more common after surgical MV replacement (SMVR) than surgical MV repair (SMVr): incidence rate 0.93 (95% CI 0.41–1.81) vs 0.39 (95% CI 0.25–0.62) per 100-patient-years, incidence rate ratio (IRR) 2.34 (95% CI 1.06–5.18), P = .035. The incidence of IE after transcatheter MV replacement (TMVR) was comparable to transcatheter MV repair (TMVr) (2.88 [95% CI 1.91–4.33] vs 1.70 [95% CI 0.84–3.43] per 100-patient-years), IRR 1.56 (95% CI 0.73–3.34), P = .250. The cumulative incidence of IE following SMVR was significantly higher than following SMVr at 1- and 2-years post-procedure, but not at 6 months. Conclusions IE is an infrequent complication of mitral valve intervention. The incidence of IE following SMVR is significantly higher than following SMVr, while the incidence of IE following TMVR is numerically but not significantly higher than following TMVr. Reducing IE risk after mitral intervention is a clinical and research priority.
Social network intervention for cardiovascular risk reduction among Hispanic and Somali adults: a cluster randomized trial
Molina, Luz, Goodson, Miriam, Capetillo, Graciela Porraz, Osman, Ahmed, Ahmed, Yahye, Nur, Omar, Iteghete, Sheila, Dirie, Hana, Clark, Matthew M. , Njeru, Jane W. , Pardo, Laura Suarez, Zeratsky, Katherine, Rieck, Thomas, Herrin, Jeph, Wieland, Mark L. , Molina, Luz, Goodson, Miriam, Ahmed, Yahye, Lohr, Abby M. , Patten, Christi A. , Zeratsky, Katherine, Rieck, Thomas , Herrin, Jeph , Valente, Thomas William , Sia, Irene G. , Wieland, Mark L , Porraz Capetillo, Graciela, Patten, Christi , Suarez Pardo, Laura, Herrin, Jeph

Mayo Clinic

Annals of Behavioral Medicine | April 13, 2026 | Volume: 60 | Issue: 1 | Pages: No page available

10.1093/abm/kaag020 | PMID 42847369 Get It

Abstract Background Immigrants to the United States often face challenges from limited healthcare access and less healthy environments which contribute to rising obesity and cardiovascular risk. Purpose To assess the feasibility and effectiveness of a community-based social network intervention for cardiovascular risk reduction among Hispanic and Somali adults. Methods A social network-informed, community-based participatory research-derived health promotion intervention was delivered by Hispanic and Somali lay health promoters (HPs) to members of their social networks over 1 year (12 biweekly sessions in months 0-6; 12 biweekly check-ins in months 7-12). Using a closed-cohort stepped wedge cluster randomized design, social networks were randomly assigned to receive the intervention immediately or after a delay of 1 year. Measurements at baseline, 6 months, and 12 months were derived from 6 of the American Heart Association’s “Life’s Simple 7”: BMI, blood pressure, fasting glucose, cholesterol, physical activity and dietary quality (range 0-12, with higher values indicating lower cardiovascular risk). Waist circumference and proportion of participants who achieved &gt;5% body weight loss were also assessed. Results Four hundred seventy-five participants were enrolled among 51 HPs (29 Hispanic; 22 Somali). There was a statistically significant improvement in cardiovascular risk in the intervention group (n = 246) compared with controls (n = 229) at 6 months (0.4 [1.8] vs. −0.1 [1.7]; P = .03) that was not sustained at 12 months (0.5 [1.9] vs. 0.3 [1.8]; P = .38). There was a statistically significant higher proportion of participants who lost &gt;5% of body weight in the intervention group compared with controls at 12 months (37% [15] vs. 18% [7.9]; P = .02). Reductions in weight and waist circumference in the intervention group compared with controls did not achieve statistical significance. Conclusion A social network intervention, delivered by lay HPs was feasible and resulted in a modest improvement of cardiovascular risk and clinically significant weight loss. Clinical Trial Identification Number NCT05136339.
Interpretable variant effect prediction from genomic foundation model representations
Pearce, Michael T, Dooms, Thomas , Yamamoto, Ryō , Ayanian, Shant , Ryu, Alexander J. , Meehl, Joshua , Molnar, Carl , Kiiskinen, Tuomo , Bissell, Mark, Hazra, Dron , Fang, Ching, Nguyen, Nam, Anderson, Michael, Osborne, Collin , Toomey, Bridget , Klee, Eric W. , Korfiatis, Panagiotis , Redlon, Matt , Jain, Archa , Balsam, Daniel, Wang, Nicholas K. , Pearce, Michael T., Dooms, Thomas, Ryu, Alexander J. , Duffy, Patrick Emmet , Myasoedova, Elena

Mayo Clinic

No container title available | April 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.04.10.717844 Get It

Abstract Scientific foundation models learn high-dimensional representations from diverse data modalities, yet what they encode and how to extract that knowledge remain open questions. Here we show that probing the internal representations of Evo 2, a 7-billion-parameter genomic foundation model, enables accurate and interpretable genetic variant effect prediction. We introduce a covariance-based probe that captures second-order structure from Evo 2 sequence embeddings to predict variant pathogenicity across variant types and functional consequences, matching or exceeding specialized predictors within their domains. To ground these predictions in known biological mechanisms, we train a complementary panel of probes on existing annotations to detect which genomic properties are disrupted by a variant. This categorized evidence is then integrated with each variant’s genomic context through a language model to generate variant-specific mechanistic hypotheses. Our pathogenicity predictions correlate with experimental measures of variant function, clinical penetrance, and biobank disease associations while the mechanistic hypotheses are consistent with expert reviews, known mechanism classes, and downstream molecular readouts. We release pathogenicity scores, disruption profiles, and contextualized interpretations for 4.2 million variants from the ClinVar database as an open resource through the Evo Variant Effect Explorer (EVEE). More broadly, this structured probing approach offers a general framework for interrogating foundation models across scientific disciplines and grounding their outputs in existing domain concepts.
CNS tumor type prevalence according to age group: An analysis of 21 000 cases confirmed by methylation profiling, with a focus on adolescents and young adults
Fonseca, Adriana , Yefet, Leeor, Singh, Omkar , Dampier, Christopher H. , Dazelle, Karen , Lam, Michelle , Abdullaev, Zied , Chung, Hye‐Jung, Quezado, Martha, Raffeld, Mark , Lee, Ina, Nasrallah, MacLean, Bennett, Julie, Bouffet, Eric, Poria, Dipak, Wesseling, Pieter, Bent, Martin van den, Wen, Patrick Y, Varlet, Pascale, Tauziède-Espariat, Arnault, Zadeh, Gelareh, Aldape, Kenneth, Singh, Omkar , Dampier, Christopher H , Quezado, Martha , Gagan, Jeffrey , Lee, Ina , Nasrallah, MacLean , Bennett, Julie , Bouffet, Eric , Poria, Dipak , Wesseling, Pieter , van den Bent, Martin J , Wen, Patrick Yung , Varlet, Pascale , Tauziède-Espariat, Arnault , Ida, Cristiane M , Zadeh, Gelareh , Aldape, Kenneth , Yefet, Leeor S. , Gagan, Jeffrey , Nasrallah, MacLean P. , Bouffet, Éric , Wesseling, Pieter , Bent, Martin J. van den , Ida, Cristiane M. , Zadeh, Gelareh

Mayo Clinic

Neuro-Oncology | April 11, 2026 | Volume: 28 | Issue: 7 | Pages: 1808-1820

10.1093/neuonc/noag082 | PMID 41978543 Get It

Abstract Background Approximately 12 000 adolescents and young adults (ages 15-39, AYAs) are diagnosed with a primary central nervous system (CNS) tumor each year. DNA methylation profiling has transformed CNS tumor classification by refining diagnostic accuracy and identifying biologically distinct subtypes, but its application has not been systematically evaluated in the AYA population. In this study, we examined the spectrum of CNS tumor types across age groups, with a focus on the AYA population. Methods We assembled a large dataset of CNS tumor samples with age annotations and methylation profiles matching with high confidence to a CNS tumor type using the NCI/Bethesda classifier. Prevalence of tumor type, methylation class and DNA copy number aberrations were compared across age strata (pediatric, AYA, and adult). Results The cohort of 21 712 CNS tumors included 5351 tumors from AYAs (25%), which showed a mixed pattern, with tumors typical of childhood (eg, medulloblastoma) as well as those common in older adults (eg, glioblastoma). Several tumor types were specifically enriched in the AYA, including IDH-mutant astrocytoma, pleomorphic xanthoastrocytoma, posterior fossa group B ependymoma, and diffuse hemispheric glioma, H3 G34-mutant, among others. Distinct methylation subclasses of multiple tumor types were observed in the AYA, and patterns of genomic aberrations showed age-specific distributions. Conclusion Large-scale methylation profiling revealed unique classification patterns of CNS tumors in AYAs, with specific tumor types, subclasses, and genomic alterations enriched in this population. These data may serve as a valuable reference resource for better understanding the spectrum of CNS tumors affecting AYA patients.